Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LIPE | Q05469 | 11/20 | 0.70 |
| ▸ | BCHE | P06276 | 1/20 | 0.52 |
| ▸ | ACHE | P22303 | 1/20 | 0.52 |
| ▸ | BACE1 | P56817 | 1/20 | 0.52 |
| ▸ | EGLN1 | Q9GZT9 | 4/20 | 0.52 |
| ▸ | P2RY1 | P47900 | 1/20 | 0.52 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.51 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL336481 | 0.85 | LIPE (0.57) | LIPEBCHEACHEBACE1 | |
| SCHEMBL5420730 | 0.84 | EGLN1 (0.58) | EGLN1 | |
| SCHEMBL5663 | 0.84 | LIPE (0.70) | LIPE | |
| SCHEMBL5662 | 0.84 | LIPE (0.70) | LIPE | |
| SCHEMBL1589109 | 0.84 | LIPE (0.70) | LIPE | |
| SCHEMBL12701929 | 0.83 | LIPE (0.56) | LIPE | |
| SCHEMBL1589501 | 0.83 | LIPE (0.56) | LIPE | |
| SCHEMBL1589502 | 0.83 | LIPE (0.56) | LIPE | |
| SCHEMBL350111 | 0.82 | LIPE (1.00) | LIPEBCHEACHEBACE1CHRM4 | |
| SCHEMBL350110 | 0.82 | LIPE (1.00) | LIPEBCHEACHEBACE1CHRM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2507239-B1 | AZACYCLIC SPIRO DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2019-03-13 | — | — | EP | claimed |
| US-8389539-B2 | Azacyclic derivatives | HOFFMAN-LA ROCHE INC. (US) | 2013-03-05 | — | — | US | claimed |
| US-20110130417-A1 | NEW AZACYCLIC DERIVATIVES | HOFFMANN-LA ROCHE, INC. | 2011-06-02 | — | — | US | claimed |
| EP-2507239-B1 | AZACYCLIC SPIRO DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2019-03-13 | — | — | EP | disclosed |
| EP-2507239-B1 | AZACYCLIC SPIRO DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2019-03-13 | — | — | EP | disclosed |
| US-20150148363-A1 | NEW AZACYCLIC COMPOUNDS | HOFFMANN-LA ROCHE INC. | 2015-05-28 | — | — | US | disclosed |
| US-20150148363-A1 | NEW AZACYCLIC COMPOUNDS | HOFFMANN-LA ROCHE INC. | 2015-05-28 | — | — | US | disclosed |
| US-20150148363-A1 | NEW AZACYCLIC COMPOUNDS | HOFFMANN-LA ROCHE INC. | 2015-05-28 | — | — | US | disclosed |
| US-20140005400-A1 | NEW AZACYCLIC COMPOUNDS | HOFFMANN-LA ROCHE INC. (US) | 2014-01-02 | — | — | US | disclosed |
| EP-2430023-B1 | AZACYCLIC SPIRODERIVATIVES AS HSL INHIBITORS | HOFFMANN LA ROCHE (CH) | 2013-12-11 | — | — | EP | disclosed |
| US-8552024-B2 | Azacyclic compounds | HOFFMAN-LA ROCHE INC. (US) | 2013-10-08 | — | — | US | disclosed |
| WO-2012020035-A1 | NEW AZACYCLIC COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-02-16 | — | — | WO | disclosed |
| US-20120041013-A1 | NEW AZACYCLIC COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-02-16 | — | — | US | disclosed |
| WO-2011067166-A1 | AZACYCLIC SPIRO DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2011-06-09 | — | — | WO | disclosed |
| WO-2011067166-A1 | AZACYCLIC SPIRO DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2011-06-09 | — | — | WO | disclosed |
| US-20110130417-A1 | NEW AZACYCLIC DERIVATIVES | HOFFMANN-LA ROCHE, INC. | 2011-06-02 | — | — | US | disclosed |
| US-20110130417-A1 | NEW AZACYCLIC DERIVATIVES | HOFFMANN-LA ROCHE, INC. | 2011-06-02 | — | — | US | disclosed |
| US-20110130417-A1 | NEW AZACYCLIC DERIVATIVES | HOFFMANN-LA ROCHE, INC. | 2011-06-02 | — | — | US | disclosed |
| WO-2010130665-A1 | AZACYCLIC SPIRODERIVATIVES AS HSL INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2010-11-18 | — | — | WO | disclosed |
| US-20100292212-A1 | NEW AZACYCLIC DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2010-11-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110130417-A1 | NEW AZACYCLIC DERIVATIVES | AZI2, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, UGT1A1 | LIPE 4817/4885BCHE 3154/4885ACHE 1965/4885 |
| US-20140005400-A1 | NEW AZACYCLIC COMPOUNDS | LIPE, GPR119, LIPC | LIPE 1/4885BCHE 405/4885ACHE 575/4885 |
| US-20100292212-A1 | NEW AZACYCLIC DERIVATIVES | GPR119, LDLR, LPL | LIPE 10/4885BCHE 1450/4885ACHE 1892/4885 |
| US-20120041013-A1 | NEW AZACYCLIC COMPOUNDS | LIPE, GPR119, LIPC | LIPE 1/4885BCHE 405/4885ACHE 575/4885 |
| US-20150148363-A1 | NEW AZACYCLIC COMPOUNDS | LIPE, GPR119, LIPC | LIPE 1/4885BCHE 405/4885ACHE 575/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.